Stocks Health care BCRX
NASDAQ · Health careBiocryst Pharmaceuticals Inc (BCRX)
Biocryst Pharmaceuticals Inc brought in $961.5M of revenue over the twelve months to September 30, 2026, up 60.3% from a year earlier. It posted a net loss of $359.7M. Operating cash flow minus capital spending left $344.9M of free cash flow in fiscal 2025. At September 30, 2026 it held $97M in cash against $395.6M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Biocryst Pharmaceuticals Inc
- Net worth
- Biocryst Pharmaceuticals Inc has a market value (market cap) of $1.9B at the latest share price, and shareholders' equity of -$397.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $874.8M (+94.1% year on year), with net income of $263.9M. Over the 12 months to September 30, 2026: revenue $961.5M, net loss $359.7M.
- Cash flow
- In fiscal 2025 operations brought in $347.4M of cash; after $2.5M of capital spending, free cash flow was $344.9M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Biocryst Pharmaceuticals Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Biocryst Pharmaceuticals Inc does
Biocryst Pharmaceuticals Inc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker BCRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $874.8M | $263.9M | $1.21 | $344.9M |
| 2024 | $450.7M | -$88.9M | -$0.43 | -$53.1M |
| 2023 | $331.4M | -$226.5M | -$1.18 | -$97.3M |
| 2022 | $270.8M | -$247.1M | -$1.33 | -$163.2M |
| 2021 | $157.2M | -$184.1M | -$1.03 | -$144.5M |
| 2020 | $17.8M | -$182.8M | -$1.09 | -$135.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where BCRX ranks in Health care
Latest SEC filings
What Biocryst Pharmaceuticals Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 13% to $180.3M versus the same quarter last year; diluted EPS $0.14 versus $0.06.
- November 4, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 5, 2026
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 34% to $218.3M versus the same quarter last year; diluted EPS $0.30 versus $0.02.
- August 5, 2026
- August 4, 2026Restructuring or layoffs 8-K/A
- June 29, 2026
- June 12, 2026
What is BCRX worth? A DCF from its reported cash flow
Insider trades
What the people running Biocryst Pharmaceuticals Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 5 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 31, 2026 | Frank StevenDirector | Received as pay | 1,288 | $12.5K |
| August 31, 2026 | McKee Amy EDirector | Received as pay | 644 | $6.2K |
| August 31, 2026 | Milano VincentDirector | Received as pay | 1,159 | $11.2K |
| August 31, 2026 | Milne Jill C.Director | Received as pay | 1,288 | $12.5K |
| August 31, 2026 | Stonehouse Jon PDirector | Received as pay | 644 | $6.2K |
| June 11, 2026 | Heggie TheresaDirector | Received as pay | 15,294 | - |
| June 11, 2026 | McKee Amy EDirector | Received as pay | 15,294 | - |
| June 11, 2026 | Stonehouse Jon PDirector | Received as pay | 15,294 | - |
Who owns BCRX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Deerfield Mgmt, L.P.13G, passive with 3 related filers | 6.81% | February 12, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 6.2% | August 14, 2026 |
| Vanguard Capital Management13G, passive | 5.16% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 318 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 23,893,036 | +1,242,048 |
| RA Capital Management, L.P. | 15,827,186 | 0 |
| State Street Corp | 15,191,098 | +2,982,738 |
| Deerfield Management Company, L.P. | 15,096,403 | +58,403 |
| Vanguard Capital Management LLC | 11,364,236 | +228,474 |
| Vanguard Portfolio Management LLC | 11,139,158 | -105,467 |
| TCG Crossover Management, LLC | 11,020,968 | 0 |
| Perceptive Advisors LLC | 10,308,888 | +2,874,855 |
| Jupiter Topco LLC | 9,540,764 | new |
| Vestal Point Capital, LP | 8,300,000 | +1,275,000 |
| Two Sigma Investments, LP | 6,775,349 | +382,721 |
| Geode Capital Management, LLC | 6,248,046 | +465,270 |
| Aberdeen Group plc | 5,310,871 | +270,201 |
| UBS Group AG | 5,078,280 | +134,286 |
| Bank of America Corp | 4,801,284 | -290,481 |
| Goldman Sachs Group Inc | 4,481,874 | +2,134,431 |
| Frazier Life Sciences Management, L.P. | 4,009,240 | 0 |
| Nuveen, LLC | 4,007,237 | +187,974 |
| Nantahala Capital Management, LLC | 3,802,320 | +1,814,923 |
| Millennium Management LLC | 3,394,729 | +3,207,008 |
Insiders
13 insiders reported holding 3,668,932 shares in total, about $28M at the last price.
| Holder | Shares |
|---|---|
| Stonehouse Jon PChief Executive Officer, Director | 1,380,41940,000 held indirectly |
| Gayer Charles KPresident and CCO | 952,583 |
| Barnes Alane PChief Legal Officer | 400,703 |
| Ghias BabarChief Financial Officer | 268,700 |
| Menon SandeepChief R&D Officer | 205,150 |
| Milano VincentDirector | 109,642 |
| Heggie TheresaDirector | 80,646 |
| Levin Alan GDirector | 79,565 |
| McKee Amy EDirector | 47,821 |
| Sanders MachelleDirector | 45,936 |
Questions about BCRX
What does Biocryst Pharmaceuticals Inc do?
Biocryst Pharmaceuticals Inc is a company in the Health care sector, listed on NASDAQ as BCRX. Its shares trade on NASDAQ under the ticker BCRX.
What is Biocryst Pharmaceuticals Inc's net worth?
Biocryst Pharmaceuticals Inc has a market value (market cap) of $1.9B at the latest share price, and shareholders' equity of -$397.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Biocryst Pharmaceuticals Inc profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $359.7M on revenue of $961.5M.
How much revenue does Biocryst Pharmaceuticals Inc make?
Over the twelve months to September 30, 2026 Biocryst Pharmaceuticals Inc reported revenue of $961.5M. That is 60.3% more than a year earlier.
When did Biocryst Pharmaceuticals Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.
When is Biocryst Pharmaceuticals Inc's next earnings report?
Biocryst Pharmaceuticals Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare BCRX with
Follow BCRX
Get an email when Biocryst Pharmaceuticals Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Biocryst Pharmaceuticals Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.